Serotonin release measured in the human brain: a PET study with [11C]CIMBI-36 and d-amphetamine challenge
David Erritzoe,Abhishekh H. Ashok,Graham E. Searle,Alessandro Colasanti,Samuel Turton,Yvonne Lewis,Mickael Huiban,Sara Moz,Jan Passchier,Azeem Saleem,John Beaver,Anne Lingford-Hughes,David J. Nutt,Oliver D. Howes,Roger N. Gunn,Gitte M. Knudsen,Eugenii A. Rabiner
DOI: https://doi.org/10.1038/s41386-019-0567-5
2019-11-12
Neuropsychopharmacology
Abstract:Positron emission tomography (PET) enables non-invasive estimation of neurotransmitter fluctuations in the living human brain. While these methods have been applied to dopamine and some other transmitters, estimation of 5-hydroxytryptamine (5-HT; Serotonin) release has proved to be challenging. Here we demonstrate the utility of the novel 5-HT2A receptor agonist radioligand, [<sup>11</sup>C]CIMBI-36, and a d-amphetamine challenge to evaluate synaptic 5-HT changes in the living human brain. Seventeen healthy male volunteers received [<sup>11</sup>C]CIMBI-36 PET scans before and 3 h after an oral dose of d-amphetamine (0.5 mg/kg). Dynamic PET data were acquired over 90 min, and the total volume of distribution (<i>V</i><sub>T</sub>) in the frontal cortex and the cerebellum derived from a kinetic analysis using MA1. The frontal cortex binding potential (BP<sub>ND</sub><sup>frontal</sup>) was calculated as (<i>V</i><sub>T</sub><sup>frontal</sup>/<i>V</i><sub>T</sub><sup>cerebellum</sup>) − 1. ∆BP<sub>ND</sub><sup>frontal</sup> = 1 − (BP<sub>ND</sub><sup>frontal</sup> post-dose/BP<sub>ND</sub><sup>frontal</sup> baseline) was used as an index of 5-HT release. Statistical inference was tested by means of a paired Students <i>t</i>-test evaluating a reduction in post-amphetamine [<sup>11</sup>C]CIMBI-36 BP<sub>ND</sub><sup>frontal</sup>. Following d-amphetamine administration, [<sup>11</sup>C]CIMBI-36 BP<sub>ND</sub><sup>frontal</sup> was reduced by 14 ± 13% (<i>p</i> = 0.002). Similar effects were observed in other cortical regions examined in an exploratory analysis. [<sup>11</sup>C]CIMBI-36 binding is sensitive to synaptic serotonin release in the human brain, and when combined with a d-amphetamine challenge, the evaluation of the human brain serotonin system in neuropsychiatric disorders, such as major depression and Parkinson's disease is enabled.
pharmacology & pharmacy,neurosciences,psychiatry